Advances in the molecular mechanisms of lacrimal glandadenoid cystic carcinoma

doi:10.3877/cma.j.issn.2095-2007.2020.03.009

Abstract

Abstract:

Lacrimal gland adenoid cystic carcinoma (LGACC) is the most common malignant epithelial tumor of the lacrimal gland, characterized by high recurrence rate and distant metastasis early. In recent years, progress has been made on the the research of molecular mechanism of LAGCC. In this paper, literatures on the biological and behavioral molecular mechanisms of adenoid cystic carcinoma at home and abroad were summarized from the aspects of its occurrence mechanism, invasion and metastasis mechanism and neurotropic growth mechanism, so as to lay a theoretical foundation for further research on the molecular mechanisms of LGACC.

Key words: Adenoid cystic carcinoma, Lacrimal gland, Molecular mechanism

Rui Liu, Jianmin Ma. Advances in the molecular mechanisms of lacrimal glandadenoid cystic carcinoma[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2020, 10(03): 177-182.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2020.03.009

https://zhykyxzz.cma-cmc.com.cn/EN/Y2020/V10/I03/177

Figures/Tables 2

References 74

[1]	Friedrich RE, Bleckmann V. Adenoid cystic carcinoma of salivary and lacrimal gland origin: localization, classification, clinical pathological correlation, treatment results and long-term follow-up control in 84 patients[J]. Anticancer Res, 2003, 23(2A): 931-940.
[2]	Sanders JC, Mendenhall WM, Werning JW. Adenoid cystic carcinoma of the lacrimal gland[J]. Am J Otolaryngol, 2016, 37(2): 144.
[3]	Zhang M, Fathy C, Breazzano MP, et al. Intra-arterial Chemotherapy for Lacrimal Gland Adenoid Cystic Carcinoma[J]. International ophthalmology clinics, 2017, 51(3): 143-152.
[4]	Von Holstein S, Rasmussen PK, Heegaard S. Tumors of the lacrimal gland[J]. Semin Diagn Pathol, 2016, 33(3): 156.
[5]	Bell D, Hanna EY. Head and neck adenoid cysticcarcinoma: What is new in biological markers and treatment[J]. Otolaryngol Head & Neck Surg, 2013, 21(2): 124-129.
[6]	Persson M, Andrén Y, Mark J, et al. Recurrentfusionof MYB and NFIB transcription factor genes in carcinomas of the breast andhead and neck[J]. Proc Natl AcadSci USA, 2009, 106(44): 18740-18744.
[7]	Mitani Y, Li J, Rao PH, et al. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinic opathologic significance[J]. ClinCancer Res, 2010, 16(19): 4722-4731.
[8]	Stenman G. Fusion oncogenes in salivary gland tumors: Molecularand clinical consequences[J]. Head Neck Pathol, 2013, 7(S1): S12-S19.
[9]	Chen TY, Keeney MG, Chintakuntlawar AV, et al. Adenoid cysticcarcinoma of thelacrimal gland isfrequentlycharacterized by MYBrearrangement[J]. Eye, 2017, 31(5): 720-725.
[10]	von Holstein SL, Fehr A, Persson M, et al. Adenoid cystic carcinoma of the lacrimal gland: MYB gene activation, genomic imbalances, and clinical characteristics[J]. Ophthalmology, 2013, 120(10): 2130-2138.
[11]	Stenman G, Andersson MK, Andren Y. New tricks from an old oncogene: Gene fusion and copy number alterations of MYB in humancancer[J]. Cell Cycle, 2010, 9(15): 2986-2995.
[12]	Yasmin D, Sara F, Bruno A, et al. Frequency and prognostic importance of translocation (6：9) (MYB-NFIB Genes) in head and neck adenoid cystic carcinoma: a systematic review[J]. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2020，129(1): e147.
[13]	Wetterskog D, Wilkerson PM, Rodrigues DN, et al. Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway，but no KIT mutations[J]. Histopathology, 2013, 62(4): 543-550.
[14]	Stenman G, Persson F, Andersson MK. Diagnosticand therapeutic implications of new molecular biomarkers in salicary gland cancer[J]. Oral Oncol, 2014, 50(8): 683-690.
[15]	Dillon P, Moskaluk C, Fracasso P, et al. Phase Ⅱ study of dovitinib (TKI258) in patients with progressive metastatic adenoid cysticcarcinoma[J]. J Clin Oncol, 2013, 20(11): 31-42.
[16]	Frierson HF, Moskaluk CA. Mutation signature of adenoid cysticcarcinoma: Evidence for transcriptional and epigenetic reprogramming[J]. J Clin Invest, 2013, 123(7): 2783-2785.
[17]	Ivanov SV, Panaccione A, Brown B, et al. TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulateinvasive behavior[J]. Oncogene, 2013, 32(32): 3698-3710.
[18]	Frerich CA, Sedam HN, Kang H, et al. N-Terminal Truncated Myb with New Transcriptional Activity Produced Through Use of an Alternative MYB Promoter in Salivary Gland Adenoid Cystic Carcinoma[J]. Cancers (Basel), 2019, 12(1): E45.
[19]	Andersson MK, Åman P, Stenman G. IGF2/IGF1R Signaling as a Therapeutic Target in MYB-Positive Adenoid Cystic Carcinomas and Other Fusion Gene-Driven Tumors[J]. Cells, 2019, 8(8): E913.
[20]	Pham T, Pereira L, Roth S, et al. First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427) [J]．Contemp Clin Trials Commun, 2019, 16: 100409.
[21]	Crittenden MR, Cottam B, Savage T, et al. Expression of NF-kappaB p50 in tumor stroma limits the control of tumors by radiationtherapy[J]. PLoS One, 2012, 7(6): e39295.
[22]	Branco KFCC, Ribeiro ALR, de Mendonça RP, et al. Abnormal activation of the Akt signaling pathway in adenoid cystic carcinoma[J]. Eur Arch Otorhinolaryngol, 2018, 275(12): 3039-3047.
[23]	Zhang J, Peng B. In Vitro Angiogenesis and Expression of Nuclear Factor KappaB and VEGF in High and Low Metastasis Cell Lines of Salivary Gland Adenoid Cystic Carcinoma[J]. BMC Cancer, 2007, 7: 95.
[24]	Wang XF, Wu DM, Li BX, et al. Synergistic inhibitory effect ofsulforaphane and 5- fluorouracil in high and low metastasis celllines of salivary gland adenoid cystic carcinoma[J]. PhytotherRes, 2009, 23(3): 303-307.
[25]	郭素珍，宋国祥，王炳亮. 泪腺肿瘤中bcl-2表达的意义[J]. 中国肿瘤临床，1998，25(123):905.
[26]	Lobry C, Oh P, Aifantis I. Oncogenic and tumor suppressorfunctions of Notch in cancer: it's NOTCH what you think[J]. J Exp Med, 2011, 208(10):1931-1935.
[27]	Liu L, Hu Y, Fu J, et al. MicroRNA155 in the growth and invasion of salivary adenoid cystic carcinoma[J]. J Oral Pathol Med, 2013, 42(2): 140-147.
[28]	Even C, Lassen U, Merchan J, et al. Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase Ⅰ trial expansion cohort of advanced or metastatic adenoid cystic carcinoma[J]. Invest New Drugs, 2020, 38(2): 402-409.
[29]	Sant DW, Tao W, Field MG, et al. Whole exome sequencing of lacrimal gland adenoid cystic carcinoma[J]. Invest Ophthalmol Vis Sci, 2017, 58(6): BIO240-BIO246.
[30]	Sajed DP, Faquin WC, Carey C, et al. Diffuse staining for activated NOTCH1 correlates with NOTCH1 mutation status and isassociated with worse outcome in adenoid cystic carcinoma[J]. AmJ Surg Pathol, 2017, 41(11): 1473-1482.
[31]	彭彩霞，王晓峰，王聪. p53抑癌基因在腺样囊性癌中的作用[J]. 现代肿瘤医学，2016，24(6):1014-1016.
[32]	Xie J, Lin LS, Huang XY, et al. The NOTCH1-HEY1 pathway regulates self-renewal and epithelial-mesenchymal transition of salivary adenoid cystic carcinoma cells[J]. Int J Biol Sci, 2020, 16(4): 598-610.
[33]	Li Q, Huang P, Zheng C, et al. Prognostic significance of p53 immunohistochemical expression in adenoid cystic carcinoma of the salivary glands: a meta-analysis[J]. Oncotarget, 2017, 8(17): 29458-29473.
[34]	Qiu L, Liu Z, Wu CZ, et al. C6-ceramide induces salivary adenoid cystic carcinoma cell apoptosis via IP3R-activated UPR and UPR-independent pathways[J]. Biochemical and Biophysical Research Communications, 2020, 525(4): 997-1003.
[35]	马赛，安峰，李立恒，等. CEACAM6在涎腺原发性腺样囊性癌中的表达及对肿瘤增殖的影响[J]. 川北医学院学报，2020，35(1):31-34.
[36]	Xu L, Li L, Zhang J, et al. Accumulated cytotoxicity of CDK inhibitor dinaciclib with first-line chemotherapy drugs in salivary adenoid cystic carcinoma cells[J]. Odontology, 2020, 108(2): 300-311.
[37]	Zhang L, Zhang H, Song GX, et al. The expression of MMP-2 and MMP-9 in adenoid cystic carcinoma of lacrimal gland[J]. Chin J Ophthalmol, 2013, 49(1): 58-63.
[38]	Sun J, Yu YC, Luo YX, et al. Expression of erythroblastic leukemia viral oncogene homolog 3 (ErbB-3) binding protein-1, matrix metalloproteinases, eplthelial cadherin in adenoid cystic carcinoma and correlation analysis[J]. Cancer, 2012, 47(12): 711-714.
[39]	Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascularendothelial growth factor gene transcription by hypoxia-inducible factor 1[J]. Mol Cell Biol, 1996, 16(9): 4604-4613.
[40]	Fan C, Tu C, Qi P, et al. GPC6 promotes cell proliferation，migration, and Invasion in nasopharyngeal carcinoma[J]. J Cancer, 2019, 10(17): 3926-3932.
[41]	鲍合刚，肖亮，孟刚，等. 涎腺腺样囊性癌中HIF-1α和BCL-2的表达及意义[J]. 临床与实验病理学杂志，2017，33(7):728-731.
[42]	王敬. 涎腺腺样囊性癌中MTA1、HIF-1α的表达及临床意义[D]. 武汉：华中科技大学，2013.
[43]	Zhanwei C, Dubin S, Shengyun H, et al. Analysis of BNIP3 expression and clinical research in salivary adenoid cystic carcinoma[J]. Hua Xi Kou Qiang Yi Xue Za Zhi, 2016, 34(4): 404-407.
[44]	Wang YF, Ma SR, Wang WM, et al. Inhibition of survivin reduces HIF-1α，TGF-β1 and TFE3 in salivary adenoid cystic carcinoma[J]. PLoS One, 2014, 9(12): e114051.
[45]	孙巧妹，林宇静. HIF-1α在唾液腺腺样囊性癌中的表达及临床意义[J]. 中外医学研究，2015，13(3):7-8.
[46]	刘佳，张美琴，于明岳，等. 唾液腺腺样囊性癌侵袭转移的研究进展[J]. 中国实验诊断学，2019，23(11):2040-2043.
[47]	Ni Q, Sun J, Ma C, et al. The Neuropilins and Their Ligands in Hematogenous Metastasis of Salivary Adenoid Cystic Carcinoma-An Immunohistochemical Study[J]. J Oral Maxillofac Surg, 2018, 76(3): 569-579.
[48]	Park S, Nam SJ, Keam B, et al. VEGF and Ki-67 Overexpression in Predicting Poor Overall Survival in Adenoid Cystic Carcinoma[J]. Cancer Res Treat, 2016, 48(2): 518-526.
[49]	Stenner M, Demgensky A, Molls C, et al. Prognostic value of survivin expression in parotid gland cancer in consideration of different histological subtypes[J]. European J Cancer, 2011, 47(7): 1013-1020.
[50]	Mulay K, Puthyapurayil FM, Mohammad JA, et al. Adenoid cysticcarcinoma of the lacrimal gland: Role of nuclear surviving(BIRC5) as a prognostic marker[J]. Histopathology, 2013, 62(6): 840-846.
[51]	富凯，杨军，汪欣，等. Survivin siRNA抑制人腺样囊性癌ACC-2细胞移植瘤血管生成[J]. 第三军医大学学报，2010，32(16):1750-1753.
[52]	Qiao Z, Zou Y, Zhao H. MicroRNA-140-5p inhibits salivary adenoid cystic carcinoma progression and metastasis via targeting surviving[J]. Cancer Cell Int, 2019，19(1): 301.
[53]	Liu L, Hu Y, Fu J, et al. MicroRNA155 in the growth and invasion of salivary adenoid cystic carcinoma[J]. J Oral Pathol Med, 2013, 42(2): 140-147.
[54]	Yao X, Wang Y, Duan Y, et al. IGFBP2 promotes salivary adenoid cystic carcinoma metastasis by activating the NF-κB/ZEB1 signaling pathway[J]. Cancer Lett, 2018, 432: 38-46.
[55]	Huang Z, Liu Y, Huang Z, et al. 1，25-Dihydroxyvitamin D3 alleviates salivary adenoid cystic carcinoma progression by suppressing GPX1 expression through the NF-κB pathway[J]. Int J Oncol, 2016, 48(3): 1271-1279.
[56]	Xu D, Li D, Lu Z, et al. Type Ⅲ TGF-β receptor inhibits cell proliferation and migration in salivary glands adenoid cystic carcinoma by suppressing NF-κB signaling[J]. Oncol Rep, 2016, 35(1): 267-274.
[57]	Serocki M, Bartoszewska S, Janaszak-Jasiecka A, et al. miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target[J]. Angiogenesis, 2018, 21(2): 183-202.
[58]	Zhang MX, Zhang J, Zhang H, et al. miR-24-3p Suppresses Malignant Behavior ofLacrimal Adenoid Cystic Carcinoma byTargeting PRKCH to Regulate p53/p21 Pathway[J]. PLoS One, 2016, 11(6): e0158433.
[59]	Hao J, Jin X, Shi Y, et al. miR-93-5p enhance lacrimal glandadenoid cystic carcinoma cell tumorigenesisby targeting BRMS1L[J]. Cancer Cell Int, 2018，18(1): 72-84.
[60]	曾威，卢文辉，张志利，等. miR-582-5p在唾液腺腺样囊性癌侵袭、转移中的作用[J]. 中国口腔颌面外科杂志，2016，14(5):413-418.
[61]	Wang C, Li T, Yan F, et al. Effect of simvastatin and microRNA-21 inhibitor on metastasis and progression of human salivary adenoid cystic carcinoma[J]. Biomed Pharmacother, 2018, 105: 1054-1061.
[62]	张志利，卢文辉，曾威，等. KDM5B在唾液腺腺样囊性癌侵袭与转移中的作用[J]. 中国口腔颌面外科杂志，2017，15(1):16-19.
[63]	马宇歌. 阻断PI3K信号通路以控制唾液腺腺样囊性癌发展和转移的机制研究[C]. 昆明：第十三次全国口腔病理学术会议论文集，2019：6.
[64]	Xu ZD, Hao T, Gan YH. RhoG/Rac1 signaling pathway involved in migration and invasion of salivary adenoid cystic carcinoma cells[J]. Oral Dis, 2020, 26(2): 302-312.
[65]	Gao XL, Zheng M, Wang HF, et al. NR2F1 contributes to cancer cell dormancy, invasion and metastasis of salivary adenoid cystic carcinoma by activating CXCL12/ CXCR4 pathway[J]. BMC Cancer, 2019, 19(1): 743-754.
[66]	Jiang YP, Tang YL, Wang SS, et al. PRRX1-induced epithelial-to-mesenchymal transition in salivary adenoid cystic carcinoma activates the metabolic reprogramming of free fatty acids to promote invasion and metastasis[J]. Cell Prolif, 2020, 53(1): e12705.
[67]	陈桂军，丁素玲. 泪腺腺样囊性癌嗜神经侵袭生长机制的免疫组化探讨[J]. 中国现代药物应用，2015，9(10):1-3.
[68]	王磊峰，董玉萍，朱素芳，等. 泪腺腺样囊性癌S-100蛋白、神经细丝酸性蛋白的表达及其意义[J]. 武警医学，2014，25(12):1252-1255.
[69]	马晓周，刘麒麟，尹唯凰，等. CC趋化因子受体6在人唾液腺腺样囊性癌组织中的表达及其临床意义[J]. 吉林大学学报(医学版)，2018，44(1):147-150.
[70]	柏书博，李力，陈贵敏. 涎腺腺样囊性癌发生发展相关基因研究进展[J]. 临床军医杂志，2017，45(1):104-107.
[71]	应重华，李蜀光，何凯辉. 神经生长因子在涎腺腺样囊性癌中的研究进展[J]. 包头医学院学报，2018，34(4):130-132.
[72]	李欢，杨新杰，王维戚，等. 应用RNA-Seq技术筛选唾液腺腺样囊性癌嗜神经侵袭相关差异表达基因[J]. 中国口腔颌面外科杂志，2018，16(3):114-119.
[73]	郭佳，李欢，王珺等. 施万细胞通过NT-3/TrkC信号通路促进SACC嗜神经侵袭的研究[J]. 实用口腔医学杂志，2019，35(2):176-180.
[74]	张美，梁新华，汤亚玲. 涎腺腺样囊性癌嗜神经侵袭分子机制的研究进展[J]. 华西口腔医学杂志，2018，36(2):204-211.

分类	第一作者	发表年份	相关分子/信号通路	作用效应
发生机制	Bell^[5]	2013	多癌基因-人类核因子Ⅰ融合基因	促进
	Li^[33]	2017	p53基因	促进
	Branco^[22]	2018	B细胞淋巴瘤因子-2基因-核因子κB信号通路和蛋白激酶B信号通路	促进
	Xie^[32]	2020	带有YRPW基序1的hes相关家族bHLH转录因子-Notch信号通路	促进
	马赛^[35]	2020	癌胚抗原相关细胞黏附分子6	促进
侵袭转移机制	Sun^[38]	2012	金属基质蛋白酶家族信号通路	促进
侵袭转移机制	Zhang^[37]	2013	金属基质蛋白酶家族信号通路	促进
	Liu^[53]	2013	miRNA-155和表皮生长因子受体-核因子κB途径	上调促进
	Park^[48]	2016	血管内皮生长因子	促进
	Huang^[55]	2016	1，25-二羟基维生素D3和核因子κB-人谷胱甘肽过氧化物酶-1-激酶型纤溶酶原激活剂途径	抑制
	Xu^[56]	2016	Ⅲ型转化生长因子β-核因子κB信号	抑制
	Zhang^[58]	2016	miRNA-24-3p和p53-p21信号通路	下调抑制
	曾威^[60]	2016	miRNA-582-5p和叉头框蛋白C1基因	上调抑制
	鲍合刚^[41]	2017	低氧诱导因子-1α	促进
	张志利^[62]	2017	组蛋白去甲基化酶KDM5B和蛋白激酶B信号通路	上调促进
	Yao^[54]	2018	胰岛素样生长因子结合蛋白2和核因子κB-E盒结合锌指蛋白1信号通路	促进
	Hao^[59]	2018	miRNA-93-5p和Wnt信号通路	下调促进
	Wang^[61]	2018	miRNA-21	上调促进
	Qiao^[52]	2019	miRNA-140-5p和生存素survivin	下调促进
	Gao^[65]	2019	核受体亚族2F组成员1和趋化因子(CXCL12)及其受体(CXCR4)途径	促进
	Xu^[64]	2020	ras同源物基因家族成员G-Ras相关的C3肉毒素底物1信号通路	促进
	Jiang^[66]	2020	同源框蛋白1-过氧化物酶体增殖物激活受体γ2-游离脂肪酸信号通路	促进
嗜神经生长机制	马晓周^[69]	2018	CC趋化因子受体CCR6	促进
	郭佳^[73]	2019	施万细胞和NT-3-酪氨酸激酶C信号通路	促进

分类	第一作者	发表年份	相关分子/信号通路	作用效应
发生机制	Bell^[5]	2013	多癌基因-人类核因子Ⅰ融合基因	促进
	Li^[33]	2017	p53基因	促进
	Branco^[22]	2018	B细胞淋巴瘤因子-2基因-核因子κB信号通路和蛋白激酶B信号通路	促进
	Xie^[32]	2020	带有YRPW基序1的hes相关家族bHLH转录因子-Notch信号通路	促进
	马赛^[35]	2020	癌胚抗原相关细胞黏附分子6	促进
侵袭转移机制	Sun^[38]	2012	金属基质蛋白酶家族信号通路	促进
侵袭转移机制	Zhang^[37]	2013	金属基质蛋白酶家族信号通路	促进
	Liu^[53]	2013	miRNA-155和表皮生长因子受体-核因子κB途径	上调促进
	Park^[48]	2016	血管内皮生长因子	促进
	Huang^[55]	2016	1，25-二羟基维生素D3和核因子κB-人谷胱甘肽过氧化物酶-1-激酶型纤溶酶原激活剂途径	抑制
	Xu^[56]	2016	Ⅲ型转化生长因子β-核因子κB信号	抑制
	Zhang^[58]	2016	miRNA-24-3p和p53-p21信号通路	下调抑制
	曾威^[60]	2016	miRNA-582-5p和叉头框蛋白C1基因	上调抑制
	鲍合刚^[41]	2017	低氧诱导因子-1α	促进
	张志利^[62]	2017	组蛋白去甲基化酶KDM5B和蛋白激酶B信号通路	上调促进
	Yao^[54]	2018	胰岛素样生长因子结合蛋白2和核因子κB-E盒结合锌指蛋白1信号通路	促进
	Hao^[59]	2018	miRNA-93-5p和Wnt信号通路	下调促进
	Wang^[61]	2018	miRNA-21	上调促进
	Qiao^[52]	2019	miRNA-140-5p和生存素survivin	下调促进
	Gao^[65]	2019	核受体亚族2F组成员1和趋化因子(CXCL12)及其受体(CXCR4)途径	促进
	Xu^[64]	2020	ras同源物基因家族成员G-Ras相关的C3肉毒素底物1信号通路	促进
	Jiang^[66]	2020	同源框蛋白1-过氧化物酶体增殖物激活受体γ2-游离脂肪酸信号通路	促进
嗜神经生长机制	马晓周^[69]	2018	CC趋化因子受体CCR6	促进
	郭佳^[73]	2019	施万细胞和NT-3-酪氨酸激酶C信号通路	促进

Please choose a citation manager

Content to export